Analysis Antimony Resources: The Clock Is Ticking on Bald Hill’s Promise
The gap between a junior miner’s ambition and its balance sheet is rarely measured in metres of drill core. For Antimony Resources, it is now measured in cash burn. The...
Top Stories
Latest financial market updates and expert analysis
AI & Quantum Computing
View All
Defense & Aerospace
View All
Cryptocurrency
View All
Banking & Finance
View All
Latest News
Analysis
Heliad Equity: The Valuation Gap That Won’t Close
The math is stark, and retail investors keep doing it. Heliad’s tender offer stands at €14.25 per share, while the...
Analysis
Intuitive Surgical: The 100% Renewal Rate That’s Being Overshadowed by the Sell-Off
The most telling number in Intuitive Surgical’s recent communications isn’t a price target or a revenue projection — it’s 100...
Analysis
SK Hynix’s Tricky Balancing Act: Wage Deal Sealed, Japan Plant Still a Question Mark
The memory-chip giant has plenty on its plate this week. A tentative wage agreement with its South Korean union, a...
Analysis
Rocket Lab’s Market Math: Why Record Operations and a Falling Share Price Can Both Be True
The numbers coming out of Rocket Lab’s operations read like a growth investor’s wish list. Second-quarter revenue hit $234 million,...
Analysis
Micron’s Split Screen: Record Backlog Meets a Wall Street Reality Check
The arithmetic coming out of Micron Technology these days is almost impossible to ignore. The memory-chip maker has locked in...
Analysis
Novo Nordisk’s Balancing Act: A Failed Heart Study, a Legal Win, and a Quiet Bet on Smaller Doses
The Danish pharmaceutical giant is navigating one of its most consequential stretches in years, juggling a clinical setback, a courtroom...
Commodities
Silver’s Rally Nears a Critical Inflection Point as a Historic Supply Gap Widens Beneath the Surface
Silver’s latest advance has carried the metal to the doorstep of a level that chartists have been watching for weeks....
Earnings
NurExone’s 30-for-1 Share Consolidation: A High-Stakes Bet on US Market Access
The arithmetic is stark: thirty shares become one. That is the proposal NurExone Biologic will put before shareholders at its...
Earnings
Lenzing’s Recovery Has a Ceiling: Why the Fibre Maker’s Rebound Remains a Work in Progress
The market’s verdict on Lenzing is split down the middle. The Austrian fibre producer’s stock has clawed back roughly 21...
Cannabis
Trulieve’s Regulatory Chessboard: DEA Filing Adds Momentum as Q2 Losses Tell a Two-Sided Story
The cannabis giant’s Wall Street honeymoon is getting a second act. Trulieve rang the NYSE closing bell on Tuesday to...